Accordingly, selective BH3 mimetics synergistically improved TTM efficacy by inducing apoptosis in BRAF-mutant melanoma, both drug-naïve and resistant to BRAF or MEK1/2 inhibitors [160]. The gene discussed is BRAF; the disease is melanoma.